Appln. No. 10/516,688 Amd. dated August 7, 2006 Reply to Office Action of February 7, 2006

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:
Listing of Claims:

Claims 1-2. (Cancelled)

- 3. (Currently Amended) A method <u>for</u> of treatment of metabolic bone disease, comprising administering <u>an</u>

 <u>effective amount of erythropoietin for said treatment</u> to a patient with renal failure-associated metabolic bone disease.
- 4. (Currently Amended) The method $\frac{for}{of}$ treatment according to claim 3, comprising administering erythropoietin in a usual dose of 0.1 to 500 μg , preferably 5 to 100 μg , per adult.
- 5. (Currently Amended) The method for of treatment according to claim 3, wherein said patient with said renal failure-associated metabolic bone disease is a patient with renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, or renal failure-associated osteoporosis.

Claims 6-7. (Cancelled)

8. (New) The method of claim 4 wherein said usual dose is 5 to 100 μg .